191 related articles for article (PubMed ID: 25333837)
1. Late toxicity of a novel allogeneic stem cell transplant using single fraction total body irradiation for hematologic malignancies in children.
Madden LM; Ngwube AI; Shenoy S; Druley TE; Hayashi RJ
J Pediatr Hematol Oncol; 2015 Mar; 37(2):e94-e101. PubMed ID: 25333837
[TBL] [Abstract][Full Text] [Related]
2. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
[TBL] [Abstract][Full Text] [Related]
3. Early outcomes after allogeneic hematopoietic SCT in pediatric patients with hematologic malignancies following single fraction TBI.
Druley TE; Hayashi R; Mansur DB; Zhang QJ; Barnes Y; Trinkaus K; Witty S; Thomas T; Klein EE; DiPersio JF; Adkins D; Shenoy S
Bone Marrow Transplant; 2009 Feb; 43(4):307-14. PubMed ID: 19011666
[TBL] [Abstract][Full Text] [Related]
4. Cytokine release syndrome after allogeneic stem cell transplantation with posttransplant cyclophosphamide.
Solán L; Landete E; Bailén R; Dorado N; Oarbeascoa G; Anguita J; Díez-Martín JL; Kwon M
Hematol Oncol; 2020 Oct; 38(4):597-603. PubMed ID: 32592410
[TBL] [Abstract][Full Text] [Related]
5. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
Long GD; Amylon MD; Stockerl-Goldstein KE; Negrin RS; Chao NJ; Hu WW; Nademanee AP; Snyder DS; Hoppe RT; Vora N; Wong R; Niland J; Reichardt VL; Forman SJ; Blume KG
Biol Blood Marrow Transplant; 1997 Dec; 3(6):324-30. PubMed ID: 9502300
[TBL] [Abstract][Full Text] [Related]
6. Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies.
Olsson RF; Logan BR; Chaudhury S; Zhu X; Akpek G; Bolwell BJ; Bredeson CN; Dvorak CC; Gupta V; Ho VT; Lazarus HM; Marks DI; Ringdén OT; Pasquini MC; Schriber JR; Cooke KR
Leukemia; 2015 Aug; 29(8):1754-62. PubMed ID: 25772027
[TBL] [Abstract][Full Text] [Related]
7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
8. The impact of total body irradiation-based regimens on outcomes in children and young adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.
Friend BD; Bailey-Olson M; Melton A; Shimano KA; Kharbanda S; Higham C; Winestone LE; Huang J; Stieglitz E; Dvorak CC
Pediatr Blood Cancer; 2020 Feb; 67(2):e28079. PubMed ID: 31724815
[TBL] [Abstract][Full Text] [Related]
9. Outcome of single fraction total body irradiation-conditioned stem cell transplantation in younger children with malignant disease--comparison with a busulphan-cyclophosphamide regimen.
Lähteenmäki PM; Chakrabarti S; Cornish JM; Oakhill AH
Acta Oncol; 2004; 43(2):196-203. PubMed ID: 15163170
[TBL] [Abstract][Full Text] [Related]
10. Pubertal outcomes of children transplanted with allogeneic stem cells after myeloablative total body irradiation or busulfan: Influence of age and sex is confirmed, while a role of chronic graft-versus-host disease in delayed puberty onset is revealed.
Weinhard S; Wiedemann A; Leheup B; Dalle JH; Lebon Labich B; Pochon C
Pediatr Transplant; 2020 Sep; 24(6):e13773. PubMed ID: 32701220
[TBL] [Abstract][Full Text] [Related]
11. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
[TBL] [Abstract][Full Text] [Related]
12. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for acute GVHD and survival after hematopoietic cell transplantation.
Jagasia M; Arora M; Flowers ME; Chao NJ; McCarthy PL; Cutler CS; Urbano-Ispizua A; Pavletic SZ; Haagenson MD; Zhang MJ; Antin JH; Bolwell BJ; Bredeson C; Cahn JY; Cairo M; Gale RP; Gupta V; Lee SJ; Litzow M; Weisdorf DJ; Horowitz MM; Hahn T
Blood; 2012 Jan; 119(1):296-307. PubMed ID: 22010102
[TBL] [Abstract][Full Text] [Related]
14. Effect of the duration between total body irradiation and stem cell infusion on the outcome of allogeneic transplantation with myeloablative conditioning.
Akahoshi Y; Kako S; Nakano H; Ugai T; Wada H; Yamasaki R; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Ashizawa M; Terasako-Saito K; Kimura S; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Nishida J; Kanda Y
Hematology; 2015 Aug; 20(7):410-5. PubMed ID: 25437012
[TBL] [Abstract][Full Text] [Related]
15. Fractionated TBI correlates with less T cell mixed chimerism but increased risk of relapse compared to busulphan in patients with haematological malignancies after allogeneic stem cell transplantation.
Mattsson J; Uzunel M; Remberger M; Hassan M
Bone Marrow Transplant; 2003 Sep; 32(5):477-83. PubMed ID: 12942093
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis.
Edahiro T; Kawase T; Nagoshi H; Fujino K; Toishigawa K; Miyama T; Mino T; Yoshida T; Morioka T; Hirata Y; Noma M; Fujii T; Nishizawa M; Fukushima N; Ichinohe T
Hematology; 2021 Dec; 26(1):186-198. PubMed ID: 33594942
[TBL] [Abstract][Full Text] [Related]
17. Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.
van Besien K; Devine S; Wickrema A; Jessop E; Amin K; Yassine M; Maynard V; Stock W; Peace D; Ravandi F; Chen YH; Cheung T; Vijayakumar S; Hoffman R; Sosman J
Bone Marrow Transplant; 2003 Jul; 32(1):9-13. PubMed ID: 12815472
[TBL] [Abstract][Full Text] [Related]
18. Single center experience with total body irradiation and melphalan (TBI-MEL) myeloablative conditioning regimen for allogeneic stem cell transplantation (SCT) in patients with refractory hematologic malignancies.
Bhatnagar B; Rapoport AP; Fang HB; Ilyas C; Marangoz D; Akbulut V; Ruehle K; Badros A; Yanovich S; Akpek G
Ann Hematol; 2014 Apr; 93(4):653-60. PubMed ID: 24097082
[TBL] [Abstract][Full Text] [Related]
19. A dose escalation study of total body irradiation followed by high-dose etoposide and allogeneic blood stem cell transplantation for the treatment of advanced hematologic malignancies.
Sobecks RM; Daugherty CK; Hallahan DE; Laport GF; Wagner ND; Larson RA
Bone Marrow Transplant; 2000 Apr; 25(8):807-13. PubMed ID: 10808200
[TBL] [Abstract][Full Text] [Related]
20. Total body irradiation, fludarabine, melphalan, and allogeneic hematopoietic stem cell transplantation for advanced pediatric hematologic malignancies.
Petropoulos D; Worth LL; Mullen CA; Madden R; Mahajan A; Choroszy M; Ha CS; Champlin RC; Chan KW
Bone Marrow Transplant; 2006 Mar; 37(5):463-7. PubMed ID: 16435013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
